| abstract |
Refers to a compound of formula I, in which X14 can be an amino acid residue with a functionalized -NH2 side chain group, with -ZC (O) -R5, in which Z represents a linker in all stereoisomeric forms and R5 is a moiety comprising up to 50 carbon atoms and heteroatoms selected from N and O; X20, X29 and X31 represent an amino acid residue; R1 is NH2 or OH, or a salt or solvate thereof; said peptide compound has a relative activity of at least 5% compared to that of natural glucagon at the glucagon receptor; it also refers to a pharmaceutical composition comprising at least one compound or a pharmaceutically acceptable salt and at least one additional pharmaceutically active ingredient. Said compound acts as a trigonal agonist of the GLP-1 / glucagon / GIP receptors and is useful in the treatment of metabolic syndrome disorders, including diabetes and obesity, as well as in reducing excess food intake. |